Early revascularization is beneficial across all ages and a wide spectrum of cardiogenic shock severity: A pooled analysis of trials.
BACKGROUND
A pooled analysis in cardiogenic shock due to acute coronary syndromes is desirable to assess the effect of early revascularization (ERV) across all ages and a wide spectrum of disease severity.


METHODS
Only two randomized controlled trials (RCT), i.e. SMASH and SHOCK, met the inclusion criteria and were combined for a pooled analysis using individual patient data (n = 348).


RESULTS
SMASH patients (n = 54, 16%) had more severe disease than SHOCK patients (n = 294, 84%). After adjustment for age, anoxic brain damage, non-inferior myocardial infarction, prior coronary artery bypass graft surgery, renal failure, systolic blood pressure, and selection for coronary angiography, one-year mortality was similar (relative risk SHOCK versus SMASH 0.87, 95% CI: 0.61-1.25). Relative risk of one-year death for ERV versus initial medical stabilization was 0.82 (95% CI: 0.70-0.96). There was no significant difference in the treatment effect by age (≤75 years relative risk at one year 0.79, 95% CI: 0.63-0.99; > 75 years relative risk at one year 0.93, 95% CI: 0.56-1.53; interaction P = 0.10).


CONCLUSIONS
Only two RCT have been published emphasizing the difficulty of enrolling critically ill patients. Despite large differences in shock severity, ERV benefit is similar across all ages and not significantly different for the elderly.
Cardiovascular Clinical Research Center, New York University School of Medicine, New York, NY, USA. rjeger@uhbs.ch
Raban V
RV
Jeger
Philip
P
Urban
Shannon M
SM
Harkness
Chi-Hong
CH
Tseng
Jean-Christophe
JC
Stauffer
Thierry H
TH
Lejemtel
Lynn A
LA
Sleeper
Matthias E
ME
Pfisterer
Judith S
JS
Hochman
D000367:Age Factors; D000368:Aged; D006801:Humans; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications; D009204:Myocardial Revascularization; D016032:Randomized Controlled Trials as Topic; D012770:Shock, Cardiogenic / Q000209:etiology / Q000401:mortality / Q000601:surgery*; D013997:Time Factors; D016896:Treatment Outcome
N Engl J Med. 1994 Jun 16;330(24):1724-30
8190135
J Am Coll Cardiol. 1991 Mar 1;17(3):599-603
1993776
Lancet. 2003 Aug 2;362(9381):392-4
12907014
J Am Coll Cardiol. 1992 Apr;19(5):915-7
1552111
Curr Opin Crit Care. 2004 Dec;10(6):570-3
15616403
Crit Care Clin. 2001 Apr;17(2):391-410
11450323
JAMA. 2007 May 2;297(17):1892-900
17473299
Rev Cardiovasc Med. 2003 Summer;4(3):131-5
12949441
JAMA. 2007 Apr 18;297(15):1657-66
17387132
Heart. 2000 Jun;83(6):621-6
10814616
Am Heart J. 2005 Jun;149(6):962-3
15976775
Circulation. 2004 Aug 3;110(5):588-636
15289388
Am J Cardiol. 2001 Apr 1;87(7):844-8
11274938
Circulation. 1988 Dec;78(6):1345-51
2973377
Curr Opin Crit Care. 2004 Dec;10(6):574-8
15616404
Am Heart J. 2005 Jun;149(6):1128-34
15976798
Circulation. 2003 Jun 24;107(24):2998-3002
12821585
Eur Heart J. 2003 May;24(9):828-37
12727150
Eur Heart J. 1999 Jul;20(14):1030-8
10383377
Am J Cardiol. 2002 Oct 15;90(8):838-42
12372570
N Engl J Med. 1999 Aug 26;341(9):625-34
10460813
J Am Coll Cardiol. 1992 Mar 1;19(3):639-46
1538022
JAMA. 2006 Jun 7;295(21):2511-5
16757723
Am Heart J. 2005 Jan;149(1):98-103
15660040
Eur Heart J. 2003 Jul;24(14):1279-81
12871682
Lancet. 2000 Aug 26;356(9231):749-56
11085707
Circulation. 1997 Jul 1;96(1):122-7
9236426
Eur Heart J. 1999 Jul;20(14):987-8
10381846
Intensive Care Med. 2006 Dec;32(12):2020-5
17019555
N Engl J Med. 1999 Apr 15;340(15):1162-8
10202167
JAMA. 2001 Jan 10;285(2):190-2
11176812
Am Heart J. 2002 May;143(5):768-76
12040336
J Am Coll Cardiol. 1992 Apr;19(5):907-14
1552110
Am Heart J. 1999 Feb;137(2):313-21
9924166
Ann Intern Med. 1999 Jul 6;131(1):47-59
10391815